SLGLHealthcare · BiotechnologyThe 3 Wall Street analysts covering Sol-Gel Technologies Ltd. hold a median 12-month price target of $153 — +116.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 45 of 100 as at 8 Oct 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Sol-Gel Technologies Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (80): The shares have been drifting up relative to others.
Growth (20): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on SLGL, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +116.8% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 20 July 2026 | HC Wainwright & Co. | Reiterates | Buy | $110 |
| 24 June 2026 | Mizuho | Initiates | Outperform | $285 |
| 24 June 2026 | Mizuho | Initiates | Outperform | — |
| 20 Jan 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 22 Dec 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 27 Oct 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 19 Aug 2024 | Raymond James | Downgrade | Outperform | — |
| 22 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 May 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 13 Nov 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 14 Aug 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 11 Aug 2023 | Raymond James | Maintains | Strong Buy | — |
| 24 July 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 July 2023 | Raymond James | Maintains | Strong Buy | — |
| 5 June 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 Apr 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 Mar 2023 | Raymond James | Maintains | Strong Buy | — |
| 1 Feb 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 Nov 2022 | HC Wainwright & Co. | Maintains | Buy | — |
| 11 Nov 2022 | Raymond James | Maintains | Strong Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SLGL appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 8 Oct 2026, Sol-Gel Technologies Ltd. returned +78.9% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 98% of US stocks
Cheaper than 3% of US stocks
Cheaper than 19% of US stocks
Cheaper than 85% of US stocks
Higher than 2% of US stocks
Higher than 2% of US stocks
Higher than 6% of US stocks
Higher than 30% of US stocks
Higher than 24% of US stocks
Higher than 17% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Sol-Gel Technologies Ltd. has a market value of $247.6M and an enterprise value of $200.5M.
Revenue in the twelve months to 30 June 2026: $1.8M. The latest quarter shrank 96.6% year on year.
Net income over the same four quarters: −$16.3M, a −910.1% net margin.
Trailing P/E: −34.8×; forward P/E: −9.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Sol-Gel Technologies Ltd. employs 28 people — $64K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Sol-Gel Technologies Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research upgraded SolGel Technologies (SLGL) to Zacks Rank #2 (Buy), citing growing optimism about the company’s earnings prospects. The excerpt says this might drive the stock higher in the near term.
Why it matters — The upgrade signals improved optimism about SLGL’s earnings prospects, which may be relevant to investors following the company.
Sol-Gel Technologies announced it will host a KOL Investor Event for its SGT-610 (patidegib gel, 2%) product on October 14, 2026 in New York. The event was announced on September 30, 2026 by the dermatology company.
Why it matters — The investor event provides an opportunity for Sol-Gel to present SGT-610 to key opinion leaders and investors, offering insight into a pipeline product for the company.
Zacks Investment Research reported that SolGel Technologies stock has formed a hammer chart pattern, suggesting it found support after recent losses. The report also noted strong agreement among Wall Street analysts in revising earnings estimates higher.
Why it matters — A SLGL watcher would care because the technical chart pattern combined with upward analyst earnings revisions points to potential for a near-term turnaround in the stock.
Sol-Gel Technologies announced that the last patient has completed the last scheduled study visit in the pivotal Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome. Top-line results remain on track for late November 2026.
Why it matters — This marks completion of patient visits in a pivotal Phase 3 trial that could determine the regulatory path for SGT-610, a key candidate in Sol-Gel's pipeline.
Sol-Gel Technologies announced its financial results for the second quarter ended June 30, 2026, and provided a corporate update. The announcement was made on August 20, 2026, from the company's headquarters in Ness Ziona, Israel.
Why it matters — A SLGL watcher would care because the quarterly financial results and corporate update provide insight into the company's recent performance and strategic direction.
The 3 Wall Street analysts covering Sol-Gel Technologies Ltd. have a median 12-month price target of $153, with estimates ranging from $110 to $195. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering Sol-Gel Technologies Ltd., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Sol-Gel Technologies Ltd. 45 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Oct 2026, Sol-Gel Technologies Ltd. ranks 45 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (80 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies +116.8% from the last close, and Ticker Nerd's factor model ranks Sol-Gel Technologies Ltd. 45 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Sol-Gel Technologies Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SLGL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $110 to $195 over the next 12 months.
Sol-Gel Technologies Ltd. returned +78.9% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Sol-Gel Technologies Ltd. is a clinical-stage dermatology company focused on developing and commercializing topical treatments for skin diseases.
The most recent item we track (Zacks Investment Research, 8 Oct 2026): "SolGel Technologies (SLGL) Upgraded to Buy: Here's Why". Zacks Investment Research upgraded SolGel Technologies (SLGL) to Zacks Rank #2 (Buy), citing growing optimism about the company’s earnings prospects. The excerpt says this might drive the stock higher in the near term.
Sol-Gel Technologies Ltd. is a clinical-stage dermatology company focused on developing and commercializing topical treatments for skin diseases. Its current portfolio includes approved products for acne vulgaris and papulopustular rosacea, alongside a pipeline of dermatology candidates aimed at severe and rare skin conditions such as Gorlin syndrome and other hyperkeratosis-related disorders. The company also works on generic topical drug products and uses its proprietary silica-based microencapsulation technology to improve the stability, tolerability, and delivery of active ingredients. Sol-Gel Technologies Ltd. serves healthcare markets in Israel and internationally, with its products and development programs positioned within medical dermatology and specialty pharmaceuticals. Founded in 1997 and headquartered in Ness Ziona, Israel, the company operates as a focused participant in the treatment of skin disorders through targeted topical therapies.
CEO Mr. Moshe Arkin · 28 employees · Israel · https://www.sol-gel.com
